TORONTO, July 8, 2026
Satellos Bioscience Inc. announced encouraging six-month interim data from its ongoing Phase 2 TRAILHEAD clinical trial evaluating SAT-3247 in adults living with Duchenne muscular dystrophy (DMD). The results from the first four participants, aged 21 to 28 years, demonstrated consistent improvements in muscle composition, physical effort, muscle damage biomarkers, and overall safety following treatment with the investigational oral therapy. Magnetic resonance imaging (MRI) showed that all four participants experienced a reduction in muscle fat fraction, with a mean improvement of 3.7%, declining from 49.7% at baseline to 46.0% after six months, suggesting improved muscle quality. In addition, every participant showed increased TE99C, a measure of maximum upper limb effort, with a mean improvement of approximately 34%, rising from 16.1 joules/kg at baseline to 21.6 joules/kg, indicating enhanced upper limb performance. Across multiple strength assessments, including handgrip, elbow, and shoulder dynamometry, muscle strength remained stable, while the near doubling of handgrip strength observed during the earlier CL-101 study was maintained through six months of follow-up.
Safety Profile Remains Favorable with Reduced Muscle Damage Biomarkers
SAT-3247 continued to demonstrate a favorable safety and tolerability profile, with no serious treatment-emergent adverse events (TEAEs), no participant withdrawals due to adverse events, and 100% treatment compliance during an average exposure period of 186 days. Supporting the functional findings, the study also reported a 38% reduction in mean creatine kinase (CK) levels, a key biomarker of muscle damage, decreasing from 2,130 U/L at baseline to 1,315 U/L after six months. Additional clinical assessments further reinforced the therapy’s potential, with Performance of the Upper Limb (PUL 2.0) scores improving in two participants and remaining stable in the remaining two, despite the progressive nature of Duchenne muscular dystrophy. Patient-reported outcomes also showed encouraging trends, as PedsQL Multidimensional Fatigue Scale scores improved by nearly seven points, suggesting meaningful gains in fatigue-related quality of life during treatment.
Disease-Modifying Potential Supported by Regenerative Mechanism
According to Satellos, the interim data strengthen evidence that SAT-3247 may function as a disease-modifying therapy by enhancing the body’s natural muscle repair and regeneration process rather than replacing dystrophin. Unlike existing therapies that target specific genetic mutations, SAT-3247 is designed to inhibit AAK1, restoring critical regenerative signaling pathways that are disrupted in Duchenne muscular dystrophy, regardless of exon mutation status. Dr. Perry Shieh, Professor of Neurology and Pediatrics at the David Geffen School of Medicine at UCLA, noted that adults with DMD represent one of the most difficult populations in which to demonstrate treatment benefit because of advanced muscle degeneration and reduced muscle stem cell reserves. He emphasized that the observed improvements in muscle fat fraction, upper limb effort, and the overall stability across multiple clinically relevant endpoints are particularly encouraging, despite the small sample size. Company Chief Executive Officer Frank Gleeson added that the biological activity observed in TRAILHEAD supports the ongoing BASECAMP pediatric Phase 2 trial, where younger patients with greater remaining muscle mass may offer an even stronger opportunity to demonstrate clinical benefit.
Advertisement
Phase 2 Development Continues Across Adult and Pediatric DMD Studies
Satellos Bioscience is advancing SAT-3247 through two ongoing Phase 2 clinical studies designed to evaluate its potential across both adult and pediatric populations. The TRAILHEAD study will enroll up to 30 adult participants across Australia and the United States to assess long-term safety, muscle composition, function, pulmonary performance, and quality-of-life outcomes over 12 months of treatment. Meanwhile, the global BASECAMP study is evaluating SAT-3247 in ambulatory boys aged 7 to 9 years through a randomized, placebo-controlled design intended to generate proof-of-concept data supporting the therapy’s disease-modifying potential. The company remains on track to complete BASECAMP enrollment and begin enrolling patients at U.S. TRAILHEAD clinical sites during the third quarter of 2026. If future studies confirm these encouraging findings, SAT-3247 could become a first-in-class oral regenerative therapy capable of improving muscle repair and preserving function for patients living with Duchenne muscular dystrophy regardless of their underlying genetic mutation.
Source: Satellos Bioscience, press release
